BC Innovations | Apr 22, 2019
Distillery Techniques

Bacterial recA-based CRISPR system for high-efficiency gene editing

TECHNIQUES CATEGORY: Drug platforms TECHNOLOGY: Gene therapy A CRISPR-based gene editing system utilizing bacterial recA could correct disease-causing point mutations with greater efficiency than standard CRISPR-based systems. The system consists of a corrected single-strand DNA...
BC Week In Review | Sep 21, 2018
Financial News

Gene therapy company Horama closes series B at €22.5M

Horama S.A. (Paris, France) closed its series B round at €22.5 million ($26.3 million) with an additional €3.5 million ($4.1 million) investment from V-Bio Ventures. Last year, the company raised €19 million ($22.2 million) in...
BC Week In Review | Nov 10, 2017
Financial News

Horoma raises €19M for gene therapies

Horama S.A. (Paris, France) raised €19 million ($22 million) in a series B round led by Kurma Partners, Fund+, Pontifax and Idinvest Partners. According to Kurma, Horama plans to enroll the first patient in a...
BC Extra | Nov 9, 2017
Financial News

Horama raises €19M for gene therapies

Horama S.A. (Paris, France) raised €19 million ($22 million) in a series B round led by Kurma Partners, Fund+, Pontifax and Idinvest Partners. According to Kurma, Horama plans to enroll the first patient in a...
BC Innovations | Jun 1, 2017
Tools & Techniques

CRISPR feels the heat

Two days after CRISPR stocks took a hit on preclinical data showing the technology causes hundreds more unintended mutations than previously thought, companies are hitting back, questioning the study’s validity and the journal’s decision to...
BC Innovations | Mar 16, 2017
Translation in Brief

Clearer, CRISPR vision

Although the eye is a prime organ for gene editing due to its easy accessibility and shielding from the immune system, many genetic disorders are so heterogeneous that designing agents to correct each gene is...
BC Innovations | Dec 6, 2016
Distillery Therapeutics

Ophthalmic disease

INDICATION: Retinitis Mouse studies suggest inhibiting SIRT6 could help treat PDE-6B -mutant retinitis pigmentosa. In a mouse model of the disease, rod photoreceptor-specific knockout of SIRT6 increased the electrophysiological function of photoreceptors and photoreceptor survival...
BioCentury | Jun 15, 2015
Emerging Company Profile

Freshening the gene pool

Horama S.A.S. is developing two gene therapies that target mutations no other companies are working on as a way of differentiating itself from the growing fraternity of ophthalmic gene therapy companies. The company was founded...
Items per page:
1 - 8 of 8